slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 44,701-44,730
Pages 10,126
Rows per page 30
Component
44,701-44,730 of 303,780
08
The slide uses a split-layout with a dark sidebar for strategic context and a white main area for product details.BenevolentAI | Investor Conference Presentation Deck | 22 slides · BenevolentAI
Conference presentation Investor relations Beat · Market SizeLoop · Cost Of Inaction2 hits
07
The slide uses a three-column layout to compare different therapeutic modalities enabled by the same platform technology.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
11
The chart uses a dot plot format to show the occurrence of specific GI symptoms over a 29-day study period across different subjects.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet2 hits
13
Data cut date: 15Nov23BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet2 hits
14
Data cut date: 15Nov23. Pt = Platinum.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet2 hits
18
The chart is a spider plot (or swimmer plot variant) showing change in target lesion size over time for individual patients.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet2 hits
22
The slide uses a process flow diagram to map patient segments to specific dosing regimens and clinical goals.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
25
Includes comparative context to historical studies (pazopanib, pembrolizumab).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing2 hits
26
Includes decision criteria for 'Go'/'No Go' based on clinical response and PFS rates.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing2 hits
27
Includes specific adverse event data and clinical observations.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing2 hits
32
The table highlights the heavy pretreatment status of the patient population, specifically noting that a significant portion received 3 or more prior systemic therapies.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
33
Includes specific response rates, disease control rates, and confidence intervals for two patient cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
34
Waterfall plot shows best percentage change from baseline; spider plot shows change over time in weeks.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
35
This is a classic swimmer plot used in oncology clinical trials to visualize time-on-treatment and response status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
39
Mentions FDA Project Optimus, which is a regulatory initiative for dose optimization in oncology trials.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
40
The dashed box highlights the 'AXL low' expression group, showing significant anti-tumor activity.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
41
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
46
Includes specific patient counts and clinical outcomes (responses, stable disease, progressive disease).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
52
The slide uses a before-after-bridge style framing to contrast the problem (toxicity in standard bispecifics) with the solution (BA3182).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
53
The slide details the dose escalation strategy using accelerated, standard, and priming titration cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 2 hits
01
BlackRock | Results Presentation Deck | 15 slidesBlackRock | Results Presentation Deck | 15 slides · BlackRock
Conference presentation Investor relations Beat · What Is2 hits
01
Central Pacific Financial | Results Presentation Deck | 21 slidesCentral Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations 2 hits
07
Includes two pie charts showing loan composition by type and by impact status.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits
10
Includes a specific footnote explaining a spike in NPAs in 2Q23 due to two specific construction loans.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits
15
Includes a stacked bar chart for regulatory capital ratios and a bar chart for historical dividend growth.Central Pacific Financial | Results Presentation Deck | 21 slides · Central Pacific Financial
Conference presentation Investor relations Beat · Financials2 hits
01
Crocs | Investor Presentation Deck | 29 slidesCrocs | Investor Presentation Deck | 29 slides · Crocs
Pitch deck Investor relations 2 hits
28
Includes a standard legal disclaimer regarding the nature of non-GAAP financial measures.Crocs | Investor Presentation Deck | 29 slides · Crocs
Pitch deck Investor relations 2 hits
11
The slide uses a process-like flow to show how specific functionalities (Panel Design, Experimental Design, etc.) are integrated into a cloud-based solution.Cytek | Investor Conference Presentation Deck | 16 slides · Cytek
Conference presentation Investor relations Loop · Golden Circle2 hits
12
The slide uses a visual bridge connecting the hardware (NL-3000) to a list of value propositions.Cytek | Investor Conference Presentation Deck | 16 slides · Cytek
Conference presentation Investor relations Loop · Golden Circle2 hits
19
Includes footnotes regarding YOY growth consistency and additional liquidity sources.D-Wave | Investor Conference Presentation Deck | 20 slides · D-Wave
Conference presentation Investor relations Beat · Ultimate Achievement2 hits